METHODS OF TREATING MYELOID LEUKEMIA
There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent.
1 . A method of treating a myeloid leukemia, comprising administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent, thereby treating the myeloid leukemia.
2 . The method of claim 1 , wherein the myeloid leukemia is acute myeloid leukemia.
3 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is as set forth in SEQ ID NO: 1 and said chemotherapeutic agent is cytarabine.
4 . The method of claim 1 , wherein said CXCR4-antagonistic peptide has an amino acid sequence as set forth in SEQ ID NO:1.
5 . The method of claim 1 , wherein said chemotherapeutic agent is cytarabine.
6 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is administered to said subject in a daily amount between 0.1 to 10 mg per kg of body weight.
7 . The method of claim 5 , wherein cytarabine is administered to said subject in a daily amount between 1 to 10 g per square meter of body area.
8 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is administered subcutaneously.
9 . The method of claim 5 , wherein said cytarabine is administered intravenously.
10 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is administered to said subject at least one day prior to the administration of said chemotherapeutic agent.
11 . The method of claim 1 , wherein said CXCR4-antagonistic peptide is administered to said subject at least one hour prior to the administration of said chemotherapeutic agent.
12 . The method of claim 1 , wherein the myeloid leukemia is acute myeloid leukemia and wherein said CXCR4-antagonistic peptide is as set forth in SEQ ID NO: 1 and said chemotherapeutic agent is cytarabine.
13 . The method of claim 12 , wherein said cytarabine is administered to said subject in a daily amount between 1 to 10 g per square meter of body area.
14 . The method of claim 12 , wherein said cytarabine is administered to said subject in a daily amount between 1 to 10 g per square meter of body area.
15 . The method of claim 12 , wherein said CXCR4-antagonistic peptide is administered subcutaneously.
16 . The method of claim 12 , wherein said CXCR4-antagonistic peptide is administered to said subject at least one day prior to the administration of said chemotherapeutic agent.
17 . The method of claim 12 , wherein said CXCR4-antagonistic peptide is administered to said subject at least one hour prior to the administration of said chemotherapeutic agent.